CAR-T Cell Therapy

CAR-T Cell Therapy Market By Target Antigen (CD19, CD22, Others), By Application (Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Others), Industry Analysis, Trends, and Forecast 2021-2027

Report ID: BMRC 774 | Number of pages: 201 | Publish Date: Jan 2021 | Category: Lifesciences and Healthcare
The detailed market intelligence report on the Global CAR-T Cell Therapy Market applies the most effective of each primary and secondary analysis to weighs upon the competitive landscape and also the outstanding market players expected to dominate Global CAR-T Cell Therapy Market place for the forecast 2021-2027.
Scope Of The Report:
Report evaluates the growth rate and the Market value based on Market dynamics, growth inducing factors. The complete knowledge is based on latest industry news, opportunities and trends. The report contains a comprehensive Market analysis and vendor landscape in addition to a SWOT analysis of the key vendors.
Geographically, this report split global into several key Regions, revenue (Million USD) The geography (North America, Europe, Asia-Pacific, Latin America and Middle East & Africa) focusing on key countries in each region. It also covers market drivers, restraints, opportunities, challenges, and key issues in Global CAR-T Cell Therapy Market. 
Key Benefits for CAR-T Cell Therapy Market Reports 
• Global market report covers in-depth historical and forecast analysis.
• Global market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market Opportunities, Competitive Analysis, Regional and Country Level.
• Global market report helps to identify opportunities in market place.
• Global market report covers extensive analysis of emerging trends and competitive landscape.
CAR-T Cell Therapy Market Segmentation:
By Target Antigen
• CD19
• CD22
• Others
By Application
• Acute Lymphoblastic Leukemia
• Diffuse Large B-Cell Lymphoma
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o UK
o France
o Germany
o Russia
o Rest of Europe
• Asia-Pacific
o China
o South Korea
o India
o Japan
o Rest of Asia-Pacific
• LAMEA
o Latin America
o Middle East
o Africa
CAR-T Cell Therapy Market Key Players:
• AbbVie Inc.
• Adaptimmune Therapeutics PLC
• Amgen, Inc.
• Atara Biotherapeutics, Inc.
• Aurora Biopharma, Inc.
• Autolus Therapeutics PLC
• Bellicum Pharmaceuticals, Inc.
• BioAtla LLC
• bluebird bio
• Carina Biotech
• Others
This comprehensive report will provide:
• Enhance your strategic decision making
• Assist with your research, presentations and business plans
• Show which emerging market opportunities to focus on
• Increase your industry knowledge
• Keep you up-to-date with crucial market developments
• Allow you to develop informed growth strategies
• Build your technical insight
• Illustrate trends to exploit
• Strengthen your analysis of competitors
• Provide risk analysis, helping you avoid the pitfalls other companies could make
• Ultimately, help you to maximize profitability for your company.
Our Market Research Solution Provides You Answer to Below Mentioned Question:
• Which are the driving factors responsible for the growth of market?
• Which are the roadblock factors of this market?
• What are the new opportunities, by which market will grow in coming years?
• What are the trends of this market?
• Which are main factors responsible for new product launch?
• How big is the global & regional market in terms of revenue, sales and production?
• How far will the market grow in forecast period in terms of revenue, sales and production?
• Which region is dominating the global market and what are the market shares of each region in the overall market in 2021?
• How will each segment grow over the forecast period and how much revenue will these segment account for in 2027?
• Which region has more opportunities?
Interested in this report?
Get your sample now!
Table of Content
1. Chapter - Report Methodology
1.1. Research Process 
1.2. Primary Research 
1.3. Secondary Research
1.4. Market Size Estimates
1.5. Data Triangulation
1.6. Forecast Model 
1.7. USP’s of Report 
1.8. Report Description 
2. Chapter – Global CAR-T Cell Therapy Market Overview: Qualitative Analysis
2.1. Market Introduction
2.2. Executive Summary 
2.3. Global CAR-T Cell Therapy Market Classification
2.4. Market Drivers
2.5. Market Restraints
2.6. Market Opportunity
2.7. CAR-T Cell Therapy Market: Trends
2.8. Porter’s Five Forces Analysis
2.8.1. Bargaining Power of Suppliers
2.8.2. Bargaining Power of Consumers
2.8.3. Threat of New Entrants
2.8.4. Threat of Substitute Product and Services
2.8.5. Competitive Rivalry within the Industry
2.9. Market Attractiveness Analysis 
2.9.1. Market Attractiveness Analysis by Segmentation 
2.9.2. Market Attractiveness Analysis by Region 
3. Chapter - Global CAR-T Cell Therapy Market Overview: Quantitative Analysis
3.1. Global CAR-T Cell Therapy Market Revenue (USD Million), Market Share (%) and Growth Rate (%), 2018- 2027
3.2. Global CAR-T Cell Therapy Market Revenue Market Share (%), 2018- 2027
3.3. Global CAR-T Cell Therapy Market Sales (Number of Units), Market Share (%) and Growth Rate (%), 2018- 2027
3.4. Global CAR-T Cell Therapy Market Sales Market Share (%), 2018- 2027
4. Chapter – Global CAR-T Cell Therapy Market Analysis: By Target Antigen
5. Chapter – Global CAR-T Cell Therapy Market Analysis: By Application
6. Chapter - Global CAR-T Cell Therapy Market Analysis: By Manufacturer 
6.1. Global CAR-T Cell Therapy Market Revenue (USD Million), by Manufacturer, 2018 - 2027
6.2. Global CAR-T Cell Therapy Market Share (%), by Manufacturer, 2021
6.3. Global CAR-T Cell Therapy Market Sales (Number of Units), by Manufacturer, 2018 - 2027
6.4. Global CAR-T Cell Therapy Market Share (%), by Manufacturer, 2021
6.5. Global CAR-T Cell Therapy Market Price (USD/Unit), by Manufacturer, 2018 - 2027
6.6. Global CAR-T Cell Therapy Market Revenue Growth Rate (%), by Manufacturer, 2018 – 2027
6.7. Merger & Acquisition
6.8. Collaborations and Partnership
6.9. New Product Launch
7. Chapter –CAR-T Cell Therapy Market: Regional Analysis
7.1. North America
7.1.1. North America CAR-T Cell Therapy Market Revenue (USD Million) and Growth Rate (%), 2018 – 2027.
7.1.2. North America CAR-T Cell Therapy Market Revenue (USD Million) By Country, 2018 – 2027.
7.1.3. North America CAR-T Cell Therapy Revenue Market Share (%) By Country, 2018 – 2027.
7.1.4. North America CAR-T Cell Therapy Market Revenue (USD Million) and Growth Rate, By Market Segmentation, 2018 – 2027.
7.1.5. North America CAR-T Cell Therapy Market Revenue (USD Million), Market Share (%) and Growth Rate, By Market Segmentation, 2018 – 2027.
7.1.6. North America CAR-T Cell Therapy Market Sales (Number of Units) and Growth Rate (%), 2018 – 2027.
7.1.7. North America CAR-T Cell Therapy Market Sales (Number of Units) By Country, 2018 – 2027.
7.1.8. North America CAR-T Cell Therapy Sales Market Share (%) By Country, 2018 – 2027.
7.1.9. North America CAR-T Cell Therapy Market Sales (Number of Units) and Growth Rate, By Market Segmentation, 2018 – 2027.
7.1.10. North America CAR-T Cell Therapy Market Sales (Number of Units), Market Share (%) and Growth Rate, By Market Segmentation, 2018 – 2027.
7.2. Europe
7.3. Asia Pacific
7.4. Latin America
7.5. Middle East & Africa
8. Chapter - Company Profiles
8.1. AbbVie Inc.
8.1.1. Overview
8.1.2. Financials
8.1.3. Product portfolio
8.1.4. CAR-T Cell Therapy Market Revenue (USD Million) and Market Share (%), 2018 - 2021
8.1.5. CAR-T Cell Therapy Sales Market Share (%), 2018 - 2021
8.1.6. Business strategy
8.1.7. Recent developments
8.2. Adaptimmune Therapeutics PLC
8.3. Amgen, Inc.
8.4. Atara Biotherapeutics, Inc.
8.5. Aurora Biopharma, Inc.
8.6. Autolus Therapeutics PLC
8.7. Bellicum Pharmaceuticals, Inc.
8.8. BioAtla LLC
8.9. bluebird bio
8.10. Carina Biotech
8.11. CARsgen Therapeutics, Ltd.
8.12. CARTherics
8.13. Celgene
8.14. Cellectis
8.15. Celularity
8.16. Celyad SA
8.17. Creative Biolabs
8.18. DiaCarta, Inc.
8.19. Endocyte, Inc.
8.20. F1 Oncology, Inc.
8.21. Fate Therapeutics Inc.
8.22. Gilead
8.23. Humanigen, Inc.
8.24. Immune Therapeutics, Inc.
8.25. Intrexon, Corp.
8.26. Juno Therapeutics, Inc.
8.27. Kite Pharma, Inc.
8.28. Lion TCR Pte Ltd.
8.29. MaxCyte, Inc.
8.30. Mesoblast, Ltd.
8.31. Minerva Biotechnologies Corp.
8.32. Mustang Bio, Inc.
8.33. Novartis AG
8.34. Oxford BioMedica PLC.
8.35. PeproMene Bio Inc.
8.36. Pfizer, Inc.
8.37. Posedia Therapeutics Inc.
8.38. Precision Biosciences, Inc.
8.39. ProMab Biotechnologies Inc.
8.40. Servier Oncology
8.41. Sorrento Therapeutics, Inc.
8.42. TC Biopharm Ltd.
8.43. Tessa Therapeutics Pte Ltd.
8.44. TILT Biotherapeutics Ltd.
8.45. Tmunity Therapeutics Inc.
8.46. TrakCel Ltd.
8.47. Xyphos
8.48. ZIOPHARM Oncology, Inc. 
8.49. Others
9. Chapter – Market Research and Findings